Breaking News
November 19, 2017 - Retinal sensitivity linked to cognitive status in T2DM
November 19, 2017 - Dental filling failure linked to smoking, drinking and genetics
November 19, 2017 - Medicaid expansion takes a bite out of medical debt
November 19, 2017 - Study aims to involve parents in early intervention services for children with autism
November 19, 2017 - Don’t Fret Delays in Treating Colon Cancer, Study Suggests
November 19, 2017 - Yeast Infection Test: MedlinePlus Lab Test Information
November 19, 2017 - Video of blood clot contraction reveals how platelets naturally form unobtrusive clots
November 19, 2017 - UNN researchers explore modeling of cognitive dissonance phenomenon
November 19, 2017 - Verseon presents second anticoagulation candidate for clinical trials at AHA 2017
November 19, 2017 - Pregnant Asian women who develop high blood pressure at highest risk for heart failure hospitalization
November 19, 2017 - Medicare seeks comment on ways to cut costs of Part D drugs
November 19, 2017 - Tree cover linked to fewer asthma cases in polluted urban neighborhoods
November 19, 2017 - Make the Diagnosis: Hair Care Conundrum
November 19, 2017 - New techniques give blood biopsies greater promise
November 19, 2017 - Researchers identify possible genetic basis for coronary artery disease
November 19, 2017 - Stress experienced by emergency call handlers has negative impact on psychological health
November 18, 2017 - New cancer cell screening is improving childhood leukaemia treatment
November 18, 2017 - Groundbreaking study identifies protein as potential factor in cancer metastasis
November 18, 2017 - New model to test effectiveness of existing and potential CF therapies
November 18, 2017 - Staying Active May Lower Odds for Glaucoma
November 18, 2017 - Potential new autism drug shows promise in mice
November 18, 2017 - Some states roll back ‘retroactive Medicaid,’ a buffer for the poor — and for hospitals
November 18, 2017 - Selectively deleting stem cell factor promotes recovery after TBI in mice
November 18, 2017 - Breakthrough research brings new procedure closer to helping patients with blood cancer
November 18, 2017 - Dr Peter Simpson Appointed to SLAS Board of Directors
November 18, 2017 - Friendships between young children can protect against ADHD
November 18, 2017 - Old World monkeys could hold key to stop progression of rheumatoid arthritis
November 18, 2017 - Harris Health System RNs named among 20 Outstanding Nurses for 2017
November 18, 2017 - Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy
November 18, 2017 - Mount Sinai researchers identify new therapeutic target for ER+ breast cancer
November 18, 2017 - Age, CRP levels predict success in tapering of biologics in rheumatoid arthritis patients
November 18, 2017 - New dye could be used to observe electrical activity of neurons in the brain
November 18, 2017 - New study further validates use of vaginal progesterone to decrease risk of preterm birth
November 18, 2017 - Russian researcher determined range of reference values for boron in the human body
November 18, 2017 - ‘What the Health?’ Tax bill or health bill?
November 18, 2017 - Could Your Cat Give You ‘Bird Flu?’
November 18, 2017 - Vitamin D Linked to Fertility Outcomes in ART
November 18, 2017 - Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer’s disease
November 18, 2017 - Tax reform proposal could impact care for older Americans
November 18, 2017 - PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease
November 18, 2017 - Researchers receive £1.3 million to develop sight-saving imaging technology
November 18, 2017 - Novel buckypaper sensor could pave way for high-performance, affordable wearable technology
November 18, 2017 - Despite ACA cost protections, most adolescents skip regular checkups
November 18, 2017 - Stem cell treatment allows paraplegic rats to walk and regain sensory perception
November 18, 2017 - HTC analytical conference comes to the UK
November 18, 2017 - Face It: Drinking, Smoking Takes Toll on Looks: MedlinePlus Health News
November 18, 2017 - New research shows where in the brain the earliest signs of Alzheimer’s occur
November 18, 2017 - Philips announces launch of global movement to raise awareness for COPD
November 18, 2017 - University of Bristol awarded grant to reduce antibacterial drug resistance in Thailand
November 18, 2017 - New oxytocin chemical sensor could be first step towards early diagnosis of autism
November 18, 2017 - Study shows how naïve T-cells may affect tumor immunity and immunotherapy
November 18, 2017 - New studies highlight importance of cardiorespiratory fitness to reduce CVD risk
November 18, 2017 - Study finds medical cannabis is effective at reducing opioid addiction
November 18, 2017 - Specially tailored, ultrafast light pulses can trigger neurons to fire in different patterns
November 18, 2017 - Decrease in sunshine linked to rising incidence of Rickets
November 18, 2017 - Harnessing social media big data to fight against prescription drug crisis
November 18, 2017 - Researchers find way to switch tumor cells between 2D and 3D morphology
November 18, 2017 - Leaf-eating ability of beetle largely due to bacteria inside the insect
November 18, 2017 - FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors
November 18, 2017 - Adolescents underreport amphetamine use, likely unaware that adderall is amphetamine
November 18, 2017 - Study reveals a reduced risk of teenage eczema in breastfed babies
November 18, 2017 - Separating side effects could pave way for safe, effective pain medications
November 18, 2017 - Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
November 18, 2017 - Environmental triggers may play role in development of Lupus
November 18, 2017 - Review looks into conventional versus new treatment modalities in orthodontic pain management
November 17, 2017 - FDA Alert: Diphenoxylate Hydrochloride and Atropine Sulfate Tablets by Greenstone: Recall
November 17, 2017 - For older women, every movement matters
November 17, 2017 - Talking-based therapy could transform aftercare for cancer survivors
November 17, 2017 - Olympus IXplore SpinSR10 imaging system enables researchers to observe fine details in live cells
November 17, 2017 - Study explores reasons for underrepresentation of minorities in genetic cancer research
November 17, 2017 - California firm running physician practices is closing down as scrutiny ramps up
November 17, 2017 - BMI not valid measure of obesity in postmenopausal women, study shows
November 17, 2017 - Vaginal progesterone decreases the risk of premature birth in women with short cervix
November 17, 2017 - Pricey ER Tests for Chest Pain Often Unnecessary
November 17, 2017 - ‘Old’ Lungs May Be Good Transplant Options: MedlinePlus Health News
November 17, 2017 - How not to gain weight over the holidays
November 17, 2017 - Researchers map first-ever proteome of healthy human heart
November 17, 2017 - Drug used to prevent and treat malaria may also be effective for Zika virus
November 17, 2017 - One in 20 children still receiving codeine to treat pain despite warning from federal regulators
November 17, 2017 - Improving clinical trials with machine learning
New SERM Shows Promise in Advanced Breast Cancer

New SERM Shows Promise in Advanced Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity.
  • Note that the study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL.

In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity, researchers reported.

Results from a phase I study in 38 patients with metastatic breast cancer demonstrated a clinical benefit rate (stable disease ≥ 6 months) of 26.3%. including a partial response by RECIST criteria in three patients who experienced progression during prior tamoxifen therapy, according to Matthew P. Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues.

Clinical benefit was also seen in seven patients who had no prior tamoxifen treatment or who didn’t experience progression with adjuvant tamoxifen. The median progression-free survival (PFS) time was 110 days, with a 1-year PFS rate of 15%, they wrote online in the Journal of Clinical Oncology.

The study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL. At the time of data lock on March 5, 2017, seven patients had died due to metastatic breast cancer. Of the 31 patients who were alive, two did not have disease progression and 29 did.

Notably, CYP2D6 — the enzyme that converts tamoxifen to endoxifen — was not associated with either Z-endoxifen oral clearance or PFS, the study showed.

Based on these results, “The relationship between CYP2D6 genotype, endoxifen exposure, and the antitumor benefit of both drugs will be evaluated in the randomized phase II trial of Z-endoxifen and tamoxifen,” authors wrote. The trial will directly compare endoxifen (80 mg/day) with tamoxifen (20 mg/day) in women with prior aromatase inhibitor (AI) progression.

For the current study, 41 women were enrolled from March 25, 2011 to Dec. 9, 2014, and 38 were included in the maximum-tolerated dose (MTD) determination. A total of 36 patients experienced progression while on an AI, 21 while on fulvestrant (Faslodex), and 15 progressed on prior tamoxifen therapy.

Patients received 20, 40, 60, 80, 100, 120, or 160 mg of Z-endoxifen by mouth daily or until unable to continue treatment. Dose levels 40, 80, and 100 mg/day were also studied in the expansion phase of the trial. Of the 16 patients enrolled in the expansion cohorts, six were randomized to 40 mg/day, five to 80 mg/day, and five to 100 mg/day.

Dose-limiting toxicities were reported in two patients at the 60-mg dose: a pulmonary embolus after one cycle of treatment and a grade 4 hypertriglyceridemia after five treatment cycles. No eye toxicity was observed and there were no adverse effects reported in the expansion cohorts.

“Long-term studies will be necessary to fully evaluate the adverse effect profile of Z-endoxifen,” the authors said.

Other selective ER modulators (SERMs) have been shown to reduce cholesterol levels and endoxifen appears to do the same. Preliminary results suggest this new SERM reduces both total and LDL cholesterol levels.

Patients with low CYP2D6 enzyme activity exhibit significantly lower endoxifen concentrations when treated with tamoxifen, Goetz’s group pointed out. Data from this study indicate that even non-therapeutic levels of Z-endoxifen can have antitumor activity in patients experiencing progression with tamoxifen, they said.

Patients with prior tamoxifen exposure and a CYP2D6 activity score ≥2.0 generally had rapid clinical progression with a shorter median PFS compared with patients with reduced CYP2D6 metabolism and an activity score ≤1.5 (61 vs 132 days, respectively, P=0.046).

In an accompanying editorial, V. Craig Jordan, PhD, of the MD Anderson Cancer Center in Houston, said that while the value of endoxifen as a salvage therapy will be determined in future clinical studies, “this could just be the beginning of a new era. Perhaps it is the right time to consider improving women’s health with a new SERM.”

More than 30 years ago, Jordan — known as the “Father of Tamoxifen” — discovered that the drug’s anti-estrogenic properties could halt breast cancer growth, thus paving the way for SERMs.

Although AIs are the current standard of care in postmenopausal women with breast cancer, the consequences of long-term therapy remain a concern, he noted.

“Improvements in the use of SERMs may be an important first step in creating an improved quality of life for an aging population,” suggested Jordan, noting that using adjuvant tamoxifen therapy for 10 years makes it possible “to save the lives of 50% of patients with ER-positive breast cancer.”

In addition to potentially reducing risk of breast cancer recurrence, a new SERM might also improve overall health in menopausal women by lowering risk of osteoporosis, coronary heart disease, and stroke without increasing the odds of endometrial cancer, Jordan pointed out.

“It is not just about being alive; it is about being well,” he wrote.

The study was funded by the Mayo Clinic, the Regis Foundation, Prospect Creek Foundation, the George M. Eisenberg Foundation for Chanties, and the National Cancer Institute.

Goetz disclosed relevant relationships with Eli Lilly, bioTheranostics, RNA Diagnostics, Eli Lilly, and Pfizer. Co-authors disclosed multiple relevant relationships with industry.

Jordan disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-10-31T09:30:00-0400

Tagged with:

About author

Related Articles